MyMedR

Displaying all 5 publications

Abstract:

Sort:

Photoperiod-mediated rapid generation advancement in soybean (Glycine max (L.) Merr.)

Rajendran A, Ramlal A, Raju D, Saini M, Bishnoi P, Subramaniam S

Photosynth Res, 2025 Mar 19;163(2):24.
PMID: 40106154 DOI: 10.1007/s11120-025-01144-7

Soybean is a short-day crop and the long-duration variety takes 120 days for maturity. A protocol for rapid generation advancement in soybean breeding is worthwhile keeping in view its utility. The study emphasizes standardisation of physical conditions, especially using warm white and cool white light-emitting diodes to hasten flowering and pod setting in soybean (DS9712 genotype). Complete open flowers were obtained with a 16 L/8D (dark/light) photoperiod in 30 days. The results also highlighted the application of interventions of physical conditions and inputs, especially during the reproductive phase to shorten the seed-to-seed generation time by around 15 days in a low-cost method for soybean breeding. Breeding will be revolutionised in case economic speed breeding is combined with modern breeding technologies, thereby resulting in more generations per year.
Fulltext In silico analysis of angiotensin-converting enzyme inhibitory compounds obtained from soybean [Glycine max (L.) Merr.]

Ramlal A, Bhat I, Nautiyal A, Baweja P, Mehta S, Kumar V, et al.

Front Physiol, 2023;14:1172684.
PMID: 37324400 DOI: 10.3389/fphys.2023.1172684

Cardiovascular diseases (CVDs) are one of the major reasons for deaths globally. The renin-angiotensin-aldosterone system (RAAS) regulates body hypertension and fluid balance which causes CVD. Angiotensin-converting enzyme I (ACE I) is the central Zn-metallopeptidase component of the RAAS playing a crucial role in maintaining homeostasis of the cardiovascular system. The available drugs to treat CVD have many side effects, and thus, there is a need to explore phytocompounds and peptides to be utilized as alternative therapies. Soybean is a unique legume cum oilseed crop with an enriched source of proteins. Soybean extracts serve as a primary ingredient in many drug formulations against diabetes, obesity, and spinal cord-related disorders. Soy proteins and their products act against ACE I which may provide a new scope for the identification of potential scaffolds that can help in the design of safer and natural cardiovascular therapies. In this study, the molecular basis for selective inhibition of 34 soy phytomolecules (especially of beta-sitosterol, soyasaponin I, soyasaponin II, soyasaponin II methyl ester, dehydrosoyasaponin I, and phytic acid) was evaluated using in silico molecular docking approaches and dynamic simulations. Our results indicate that amongst the compounds, beta-sitosterol exhibited a potential inhibitory action against ACE I.
Boswellic Acids: A Critical Appraisal of Their Therapeutic and Nutritional Benefits in Chronic Inflammatory Diseases

Solanki N, Gupta G, Chellappan DK, Singh SK, Gulati M, Paudel KR, et al.

Endocr Metab Immune Disord Drug Targets, 2024;24(1):116-129.
PMID: 37183464 DOI: 10.2174/1871530323666230512154634

BACKGROUND: In the last few decades, it has been largely perceived that the factors affecting the immune system and its varying pathways lead to the pathological progression of inflammation and inflammatory conditions. Chronic inflammation also contributes to common diseases, such as diabetes mellitus, ischemic heart disease, cancer, chronic renal inflammatory disease, non-alcoholic fatty hepat-ic disease, autoimmune diseases and neurodegenerative diseases.
OBJECTIVE: Interestingly, plant sources and secondary metabolites from plants have been increasingly employed in managing acute and chronic inflammatory diseases for centuries. Boswellic acids are pentacyclic triterpenoidal moieties obtained from the oleo gum resin of different Boswellia species.
METHODS: Detailed data was collected revealing the anti-inflammatory potential of Boswellic acids through various databases.
RESULT: These are pharmacologically active agents that possess promising anti-inflammatory, anti-arthritic, antirheumatic, anti-diarrheal, anti-hyperlipidemic, anti-asthmatic, anti-cancer, and anti-microbial effects.
CONCLUSION: Boswellic acids have been in use since ancient times primarily to treat acute and chronic inflammatory diseases. This review discusses the various mechanisms underlying the inflammatory process and the necessity of such natural products as a medication to treat inflammatory diseases. In addition, a discussion has also been extended to understand the primary targets involved in inflammation. The review further explores the therapeutic potential of boswellic acids in.
Search for Soft Unclustered Energy Patterns in Proton-Proton Collisions at 13 TeV

Hayrapetyan A, Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, et al.

Phys Rev Lett, 2024 Nov 08;133(19):191902.
PMID: 39576923 DOI: 10.1103/PhysRevLett.133.191902

The first search for soft unclustered energy patterns (SUEPs) is performed using an integrated luminosity of 138 fb^{-1} of proton-proton collision data at sqrt[s]=13 TeV, collected in 2016-2018 by the CMS detector at the LHC. Such SUEPs are predicted by hidden valley models with a new, confining force with a large 't Hooft coupling. In events with boosted topologies, selected by high-threshold hadronic triggers, the multiplicity and sphericity of clustered tracks are used to reject the background from standard model quantum chromodynamics. With no observed excess of events over the standard model expectation, limits are set on the cross section for production via gluon fusion of a scalar mediator with SUEP-like decays.
Search for the Z Boson Decay to ττμμ in Proton-Proton Collisions at sqrt[s]=13 TeV

Hayrapetyan A, Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, et al.

Phys Rev Lett, 2024 Oct 18;133(16):161805.
PMID: 39485967 DOI: 10.1103/PhysRevLett.133.161805

The first search for the Z boson decay to ττμμ at the CERN LHC is presented, based on data collected by the CMS experiment at the LHC in proton-proton collisions at a center-of-mass energy of 13 TeV and corresponding to an integrated luminosity of 138 fb^{-1}. The data are compatible with the predicted background. For the first time, an upper limit at the 95% confidence level of 6.9 times the standard model expectation is placed on the ratio of the Z→ττμμ to Z→4μ branching fractions. Limits are also placed on the six flavor-conserving four-lepton effective-field-theory operators involving two muons and two tau leptons, for the first time testing all such operators.